Cart
×
Capricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial
Sarepta Therapeutics Receives Notification of PDUFA Extension for Eteplirsen
Catabasis Pharmaceuticals Announces Positive Top – Line Results from Part A of the MoveDMD Trial , a Phase 1 / 2 Trial of CAT – 1004 for the Treatment of Duchenne Muscular Dystrophy
SUMMIT THERAPEUTICS RECEIVES REGULATORY APPROVAL TO INITIATE PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF SMT C1100 IN PATIENTS WITH DMD
FDA Issues Complete Response Letter for KyndrisaTM for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
PTC Completes Rolling NDA Submission to FDA and Submits Phase 3 ACT DMD Clinical Trial Results to EMA for Translarna™ (ataluren) for Treatment of Nonsense Mutation Duchenne Muscular Dystrophy
Grünenthal and Akashi Therapeutics Inc. Announce Joint Drug Development Program for HT-100 in the Treatment of Patients with Duchenne Muscular Dystrophy (DMD)